Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Parenthetical) (Details)

v3.20.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Parenthetical) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Sep. 30, 2018
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenue from related parties $ 22,536 $ 18,966 $ 44,606  
Bristol-Myers Squibb Company ("BMS")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenue from related parties   $ 8,900    
Celgene        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenue from related parties $ 8,900      
Celgene | Minimum        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Ownership percentage       10.00%